Work

Observations on quality of life and disease control in patients with hereditary angioedema

Year: 2025

Type: article

Abstract: Background: Lanadelumab is administered subcutaneously at 2- to 4-week intervals for long-term prophylaxis in hereditary angioedema (HAE). The effect of longer treatment intervals on disease control or disease-related quality of life (QoL) remains elusive. Objectives: To assess whether the reduction of the burden of treatment improves QoL. Methods: The treatment outcome of 56 patients with HAE treated with lanadelumab was assessed. The last documented treatment interval was extracted from patient records; individual disease control and QoL were assessed routinely with the Angioedema Control Test (AECT) and Angioedema Quality of Life Questionnaire (AE-QoL). The evaluation was based on the duration of the injection interval, i.e. equal to or less than 28 days (L ≤ 28) or more than 28 days (L > 28). Results: In total, 56 patients were included, 23 patients with L ≤ 28 and 33 with L > 28. In the L ≤ 28 group, the mean AECT was 14 points and the AE-QoL was 24 points. In the L > 28 group, the mean AECT was 15.5 points and the AE-QoL was 11.6 points. Conclusions: We conclude that lanadelumab injection intervals can be generously individualized in many patients with HAE while fully maintaining disease control and QoL.

Source: Skin Health and Disease

DOI: 10.1093/skinhd/vzaf055

Authors: Thomas Buttgereit, Annika Gutsche, Markus Magerl

Institutions: Humboldt-Universität zu Berlin, Fraunhofer Institute for Translational Medicine and Pharmacology, Freie Universität Berlin, Charité - Universitätsmedizin Berlin

Language: English

Topic: Coagulation, Bradykinin, Polyphosphates, and Angioedema

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,597